65,437 trials
Epistaxis
Primary: This Study Evaluates the Efficacy of HemCon Hemostatic Agent in Control of Complicated Epistaxis in Terms of % Success of Hemostasis. Success Will be Defined as…
Lymphedema
Primary: Percent Volume Change of Affected Limb at End of Treatment Compared to Baseline. — -14.56; -7.09; -10.24; -9.84 % volume change measured in mL.
Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
Primary: Percentage of Participants Who Achieved Hemostasis at 4 Minutes Post Treatment Application. — 62.9; 31.4 Percentage of participants — p=<0.0001
Huntington Disease · Chorea
Primary: Conners' Adult Attention Rating Scale (CAARS) — -2.88; -2.24 units on a scale — p=0.63
Non-Small-Cell Lung Cancer
Primary: Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin — NA milligram/milliliter*minute (mg/mL*min)
Schizophrenia · Bipolar Disorder · Autistic Disorder
Primary: Height (cm) Z-score at Study Visit — 0.40; 0.09 z-score — p=<0.001
Posterior Blepharitis
Primary: Meibomian Gland Secretion Quality — 1.7; 1.7; 1.8 Units on a scale
Amphetamine-Related Disorders · HIV · HIV Infections
Primary: Self-reported Methamphetamine Use in Previous 30 Days. — 1.6 days
Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)
Primary: Percentage of Participants Achieving Hemostasis at 4 Minutes After Treatment Application at the Study Suture Line. — 46.2; 62.5; 34.8; 30.8 percentage of participants
Ulcerative Colitis
Primary: Percentage of Participants With Clinical Remission at 8 Weeks — 11.5; 13.8; 10.0 percentage of participants
Healthy
Primary: Percentage Duration With An Intragastric pH >= 4 During The Entire 24 Hours Of Day 5 Administration — 45.63; 57.81; 61.36; 71.52 Percentage of Time in a 24 Hour Period
Type II Diabetes Mellitus
Primary: HbA1c: Change From Baseline to 4 Month — -1.25; -1.26; -0.67; -0.61 Percentage
Oxytocin · Placebo
Primary: Systolic Blood Pressure Change From Baseline to Second Stress Task Experience - Autonomic Stress Response Measure — 9.4; 12.9; 11.3; 11.1 mm Hg — p=0.03
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With Seroprotection to Vaccine Antigens Following Vaccination With ADACEL Polio (TdcP-IPV) Vaccine. — 131; 131; 131; 131 Participants
Parkinson Disease
Primary: Patients With a Score of 4 in Morisky Scale After 8-12 Weeks of Treatment — 75.2 Percent